Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

In this report, inhibitors of the gamma-secretase enzyme have been exploited to characterize the antiproliferative relationship between target inhibition and cellular responses in Notch-dependent human T cell acute lymphoblastic leukemia (T-ALL) cell lines. Inhibition of gamma-secretase led to decreased Notch signaling, measured by endogenous NOTCH intracellular domain (NICD) formation, and was associated with decreased cell viability. Flow cytometry revealed that decreased cell viability resulted from a G(0)/G(1) cell cycle block, which correlated strongly to the induction of apoptosis. These effects associated with inhibitor treatment were rescued by exogenous expression of NICD and were not mirrored when a markedly less active enantiomer was used, demonstrating the gamma-secretase dependency and specificity of these responses. Together, these data strengthen the rationale for using gamma-secretase inhibitors therapeutically and suggest that programmed cell death may contribute to reduction of tumor burden in the clinic.

[1]  N. Baker,et al.  Notch signaling in the nervous system. Pieces still missing from the puzzle. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[2]  Q. Su,et al.  Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. , 2005, Cancer research.

[3]  S. Artavanis-Tsakonas,et al.  Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2 , 1997, Molecular and cellular biology.

[4]  Iva Greenwald,et al.  Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene , 1995, Nature.

[5]  I. Screpanti,et al.  Notch, a unifying target in T-cell acute lymphoblastic leukemia? , 2003, Trends in molecular medicine.

[6]  H. Weintraub,et al.  Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Klein,et al.  Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. , 2004, Developmental biology.

[8]  S. Artavanis-Tsakonas,et al.  Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. , 2004, The American journal of pathology.

[9]  H. Stein,et al.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. , 2002, Blood.

[10]  Hans Clevers,et al.  Signaling pathways in intestinal development and cancer. , 2004, Annual review of cell and developmental biology.

[11]  A. Diévart,et al.  Involvement of Notch1 in the development of mouse mammary tumors , 1999, Oncogene.

[12]  J. Kutok,et al.  Notch Oncoproteins Depend on γ-Secretase/Presenilin Activity for Processing and Function* , 2004, Journal of Biological Chemistry.

[13]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[14]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[15]  B. Osborne,et al.  Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents , 2003, Oncogene.

[16]  J. Sklar,et al.  Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the β T cell receptor gene in human lymphoblastic neoplasms , 1987, Cell.

[17]  A. Sarin,et al.  Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. , 2001, Virology.

[18]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[19]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[20]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[21]  Raphael Kopan,et al.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. , 2000, Molecular cell.

[22]  R. Hruban,et al.  Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. , 2003, Cancer cell.

[23]  T. Hampton,et al.  A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice , 2000 .

[24]  S. Pollack,et al.  Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. , 2005, Current opinion in investigational drugs.

[25]  Robert A. Copeland,et al.  Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.

[26]  G. Tonon,et al.  t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway , 2003, Nature Genetics.

[27]  H. Pass,et al.  Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells , 2003, Oncogene.

[28]  N. Gaiano,et al.  Notch signaling in the mammalian central nervous system: insights from mouse mutants , 2005, Nature Neuroscience.

[29]  T. Sparey.  Cyclic Sulfamide γ-Secretase Inhibitors. , 2005 .

[30]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[31]  J. Aster,et al.  Notch Signaling in Cancer , 2002, Cancer biology & therapy.

[32]  T. Dang,et al.  Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. , 2005, Cancer research.

[33]  M. Herlyn,et al.  Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. , 2005, The Journal of clinical investigation.

[34]  L. Miele,et al.  HPV16 E6 and E7 oncoproteins regulate Notch‐1 expression and cooperate to induce transformation , 2003, Journal of cellular physiology.

[35]  L. Miele,et al.  NOTCH signaling as a novel cancer therapeutic target. , 2006, Current cancer drug targets.

[36]  Keith Brennan,et al.  Is there a role for Notch signalling in human breast cancer? , 2003, Breast Cancer Research.

[37]  W. Hahn,et al.  Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells , 2002, Nature Medicine.

[38]  D. Ball,et al.  Notch in lung development and lung cancer. , 2004, Seminars in cancer biology.

[39]  Patrick Maisonneuve,et al.  Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis , 2004, The Journal of cell biology.

[40]  James D. Griffin,et al.  Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling , 2003, Molecular and Cellular Biology.

[41]  M. Dettke,et al.  Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. , 2002, Blood.

[42]  A. Capobianco,et al.  Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. , 2003, Cancer cell.

[43]  M. Hilgarth,et al.  Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2 , 2005, Leukemia.

[44]  K. Somasundaram,et al.  Activated Notch1 Inhibits p53-Induced Apoptosis and Sustains Transformation by Human Papillomavirus Type 16 E6 and E7 Oncogenes through a PI3K-PKB/Akt-Dependent Pathway , 2003, Journal of Virology.

[45]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[46]  M. Fortini,et al.  Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants , 1999, Nature.

[47]  Christel Brou,et al.  Signalling downstream of activated mammalian Notch , 1995, Nature.

[48]  Joel I. Pritchard,et al.  The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas , 2004, Cancer Research.

[49]  L. L. Reed,et al.  Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells , 2005, Oncogene.

[50]  J. Sklar,et al.  TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.

[51]  L. Girard,et al.  Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. , 1996, Genes & development.

[52]  A. Nadin,et al.  Catalytic Site-Directed γ-Secretase Complex Inhibitors Do Not Discriminate Pharmacologically between Notch S3 and β-APP Cleavages , 2003 .

[53]  M. Hendrix,et al.  p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. , 2004, Molecular cancer therapeutics.

[54]  S. Artavanis-Tsakonas,et al.  Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Raphael Kopan,et al.  γ-Secretase: proteasome of the membrane? , 2004, Nature Reviews Molecular Cell Biology.

[56]  Larry Kedes,et al.  HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.

[57]  J. Sklar,et al.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles , 1996, The Journal of experimental medicine.